885280-71-7 Usage
Uses
Used in Medicinal Chemistry:
7-BROMO-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YLAMINE is used as a potential drug candidate for the development of new pharmaceuticals due to its pharmacological properties. Its unique structure and functional groups contribute to its potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 7-BROMO-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YLAMINE is used as a building block for the creation of various chemical compounds. The presence of both bromine and amine groups enhances its reactivity and compatibility in synthetic pathways, facilitating the production of a wide range of organic materials.
Used in Research and Industrial Applications:
7-BROMO-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YLAMINE is also utilized in research and industrial applications due to its specific structure and properties. Its versatility and reactivity make it a valuable intermediate for exploring new chemical reactions and developing innovative products across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 885280-71-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,2,8 and 0 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 885280-71:
(8*8)+(7*8)+(6*5)+(5*2)+(4*8)+(3*0)+(2*7)+(1*1)=207
207 % 10 = 7
So 885280-71-7 is a valid CAS Registry Number.
InChI:InChI=1S/C10H12BrN/c11-9-3-1-7-2-4-10(12)6-8(7)5-9/h1,3,5,10H,2,4,6,12H2
885280-71-7Relevant articles and documents
Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors
Tang, Guozhi,Wong, Jason C.,Zhang, Weixing,Wang, Zhanguo,Zhang, Nan,Peng, Zhenghong,Zhang, Zhenshan,Rong, Yiping,Li, Shijie,Zhang, Meifang,Yu, Lingjie,Feng, Teng,Zhang, Xiongwen,Wu, Xihan,Wu, Jim Z.,Chen, Li
supporting information, p. 8026 - 8034 (2014/12/10)
Herein we report the identification of a novel class of HDAC6 and HDAC8 selective inhibitors through a unique chemistry and phenotypic screening strategy. Tetrahydroisoquinoline 12 was identified as a potent HDAC6 and HDAC8 dual inhibitor from a focused l
NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER
-
Page/Page column 17; 18, (2012/03/27)
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to proc
NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER
-
Page/Page column 54, (2012/03/27)
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to proc